Ann C Childress (Ann Childress)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 36

Top Topics

Attention Deficit Hyperactivity Disorder

Placebo Controlled

Top Venues

Journal of child and adolescent psychopharmacology

Expert opinion on pharmacotherapy

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Raman Baweja, Stephen V Faraone, Ann C Childress, Margaret Danielle Weiss, Sandra K Loo, Timothy E Wilens, James G Waxmonsky
From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. Journal of child and adolescent psychopharmacology 34 (4) (2024)
Raman Baweja, Stephen V Faraone, Ann C Childress, Margaret Danielle Weiss, Sandra K Loo, Timothy E Wilens, James G Waxmonsky
From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. Journal of child and adolescent psychopharmacology 34 (4) (2024)
Ann C Childress
Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. Expert opinion on pharmacotherapy (2024)
Ann C Childress
Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. Expert opinion on pharmacotherapy 25 (7) (2024)
Ann C Childress
Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. Expert opinion on pharmacotherapy (2024)
Raman Baweja, Stephen V Faraone, Ann C Childress, Margaret Danielle Weiss, Sandra K Loo, Timothy E Wilens, James G Waxmonsky
From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. Journal of child and adolescent psychopharmacology (2024)
Ann C Childress
Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. Expert opinion on pharmacotherapy 25 (7) (2024)
Jeff Schein, Martin Cloutier, Rebecca L Bungay, Marjolaine Gauthier-Loiselle, Ann C Childress
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder. Journal of medical economics 27 (1) (2024)
Jeff Schein, Martin Cloutier, Rebecca L Bungay, Marjolaine Gauthier-Loiselle, Ann C Childress
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder. Journal of medical economics 27 (1) (2024)
Raman Baweja, Stephen V Faraone, Ann C Childress, Margaret Danielle Weiss, Sandra K Loo, Timothy E Wilens, James G Waxmonsky
From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. Journal of child and adolescent psychopharmacology 34 (4) (2024)
Raman Baweja, Stephen V Faraone, Ann C Childress, Margaret Danielle Weiss, Sandra K Loo, Timothy E Wilens, James G Waxmonsky
From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. Journal of child and adolescent psychopharmacology 34 (4) (2024)
Raman Baweja, Stephen V Faraone, Ann C Childress, Margaret Danielle Weiss, Sandra K Loo, Timothy E Wilens, James G Waxmonsky
From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. Journal of child and adolescent psychopharmacology 34 (4) (2024)
Jeff Schein, Martin Cloutier, Rebecca L Bungay, Marjolaine Gauthier-Loiselle, Ann C Childress
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder. Journal of medical economics (2024)
Ann C Childress
Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. Expert opinion on pharmacotherapy 25 (7) (2024)
Ann C Childress, Robert Sottile, Sherine Khanbijian
Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients. Expert review of neurotherapeutics (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology (2023)
Andrew J Cutler, Katsumi Suzuki, Brittney Starling, Kanan Balakrishnan, Marina Komaroff, Suzanne Meeves, Mariacristina Castelli, Ann C Childress
d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial. Journal of child and adolescent psychopharmacology 33 (5) (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology 33 (1) (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology (2023)
Erika Ryst, Ann C Childress
An updated safety review of the current drugs for managing ADHD in children. Expert opinion on drug safety (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology 33 (1) (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology 33 (1) (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology 33 (1) (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology 33 (2) (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology 33 (1) (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology 33 (2) (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology 33 (1) (2023)
Ann C Childress, Andrew J Cutler, Maitrey Patel, Charles Oh
Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate. Journal of child and adolescent psychopharmacology 33 (4) (2023)
Stephen V Faraone, Ann C Childress, Roberto Gomeni, Eman Rafla, Judith C Kando, Lori Dansie, Payal Naik, Antonio Pardo
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of child and adolescent psychopharmacology 33 (1) (2023)
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. Journal of child and adolescent psychopharmacology 33 (2) (2023)
Ann C Childress, Kenisha R Yu, Lewis Cuthbertson
Early Morning ADHD Symptoms and Functional Impairment: Impact on Patients and Caregivers, and Pharmacological Approaches to Management. CNS drugs 37 (1) (2022)
Ann C Childress, Eric Lloyd, Steven A Johnson, Lhanoo Gunawardhana, Valerie Arnold
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder. Journal of child and adolescent psychopharmacology 32 (2) (2022)
Ann C Childress, Kenisha R Yu, Lewis Cuthbertson
Early Morning ADHD Symptoms and Functional Impairment: Impact on Patients and Caregivers, and Pharmacological Approaches to Management. CNS drugs (2022)
Ann C Childress, Kenisha R Yu, Lewis Cuthbertson
Early Morning ADHD Symptoms and Functional Impairment: Impact on Patients and Caregivers, and Pharmacological Approaches to Management. CNS drugs 37 (1) (2022)
Ann C Childress, Kenisha R Yu, Lewis Cuthbertson
Early Morning ADHD Symptoms and Functional Impairment: Impact on Patients and Caregivers, and Pharmacological Approaches to Management. CNS drugs 37 (1) (2022)
Marc J Cataldo, Graeme A E Donnelly, Andrew J Cutler, Ann C Childress, Jaromir Mikl, Sailaja Bhaskar, James G Waxmonsky
Analysis of Daily Sleep Diary Measures From Multilayer Extended-Release Methylphenidate (PRC-063) Studies in Children and Adults With ADHD. Journal of attention disorders 26 (14) (2022)